PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.23%
Positive revenue growth while ADI is negative. John Neff might see a notable competitive edge here.
-0.51%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-13.11%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-10.06%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.57%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-8.77%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-8.93%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-1.04%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.95%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.30%
Dividend reduction while ADI stands at 13.74%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
80.35%
OCF growth above 1.5x ADI's 30.69%. David Dodd would confirm a clear edge in underlying cash generation.
166.20%
FCF growth above 1.5x ADI's 35.39%. David Dodd would verify if the firm’s strategic investments yield superior returns.
173.88%
10Y revenue/share CAGR above 1.5x ADI's 89.52%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
21.32%
5Y revenue/share CAGR at 50-75% of ADI's 36.41%. Martin Whitman would worry about a lagging mid-term growth trajectory.
16.64%
3Y revenue/share CAGR 1.25-1.5x ADI's 11.46%. Bruce Berkowitz might see better product or regional expansions than the competitor.
397.80%
10Y OCF/share CAGR above 1.5x ADI's 64.92%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
257.54%
5Y OCF/share CAGR at 75-90% of ADI's 314.96%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
23.30%
3Y OCF/share CAGR at 75-90% of ADI's 26.97%. Bill Ackman would press for improvements in margin or overhead to catch up.
850.50%
Net income/share CAGR 1.25-1.5x ADI's 571.50%. Bruce Berkowitz might see more effective use of capital or consistently better margins over time.
12.70%
Below 50% of ADI's 81.57%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
21.68%
Below 50% of ADI's 53.78%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
39.50%
10Y equity/share CAGR at 50-75% of ADI's 64.68%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
20.69%
5Y equity/share CAGR is in line with ADI's 21.68%. Walter Schloss would see parallel mid-term profitability and retention policies.
24.51%
Below 50% of ADI's 50.65%. Michael Burry suspects a serious short-term disadvantage in building book value.
484.42%
Dividend/share CAGR of 484.42% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
323.55%
5Y dividend/share CAGR above 1.5x ADI's 55.72%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
28.78%
3Y dividend/share CAGR 1.25-1.5x ADI's 25.14%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
6.70%
Our AR growth while ADI is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
11.52%
Inventory growth well above ADI's 1.89%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
22.28%
Asset growth above 1.5x ADI's 1.76%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
2.19%
50-75% of ADI's 3.84%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
65.84%
We have some new debt while ADI reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-6.84%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-5.60%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.